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Variations in the Distribution, Frequency, and
Phenotype of Langerhans Cells During the Evolution
of Malignant Melanoma of the Skin
Kan Toriyama, Duan-Ren Wen, Eberhard Paul and Alistair J. Cochran
We examined the frequency, distribution, and immuno-phenotype (S-100 protein, CD1) of epidermal Langerhans cells
(LC) in the epidermis overlying primary melanoma, and dermal dendritic cells (DC) in the dermis deep to melanoma,
and in adjacent normal skin. There is a substantial reduction in S-100þ LC and a lesser decline in CD1þ LC in the
epidermis over melanoma. There is a simultaneous increase in the frequency of cells expressing these phenotypes in
the dermis deep to tumor. Double-staining studies in progress show coexpression of S-100 and CD1 in most of these
cells. The depletion of S-100þ /CD1þ DC from the peritumoral epidermis is maximum in deeper (Clark level III–V) and
thicker (40.76mm) tumors. The reduction in total DC in peritumoral epidermis is, however, proportionally less than
the reduction in S-100þ /CD1þ DC owing to an increase in cells that are S-100/CD1þ . The proportion of S-100þ /
CD1þ dermal DC deep to tumor is similar to that in normal epidermis and dermis, suggesting that there is no
increased migration of S-100/CD1þ DC from tumor-associated epidermis to subjacent dermis. Non-dendritic
leukocytes in the dermis deep to tumor were increased in frequency, maximally in the dermis deep to thinner and more
superficial melanomas. Most such cells were T lymphocytes with helper/inducer cells predominating. The data presented
show substantial alterations in the frequency, distribution, and phenotype of LC/DC as melanoma evolves, alterations that
may be critical for development of effective tumor-directed immunity. J Invest Dermatol 100:269S–273S, 1993
Langerhans cells (LC) and cells derived from them, including dendritic
cells of the dermis, veiled cells of the afferent lymphatics, and
interdigitating cells of the nodal paracortex are critical to the initiation
of T-lymphocyte-mediated cellular immunity [1,2]. In previous publica-
tions, we and others have demonstrated that the density of LC in the
epidermis and dermis adjacent to primary cutaneous melanoma differs
significantly from that in normal skin adjacent to the tumor [3–5]. Stene
et al [5] found that CD1þ LC were depleted in the epidermis superficial to
deeply invasive melanomas but were less reduced in frequency in the
epidermis above in situ and early invasive melanomas. CD1þ dermal
dendritic cells (DC) were significantly increased around in situ and early
invasive melanomas but not around deeply invasive primary melanomas
or cutaneous metastases of melanoma. There was a progressive decline in
the density of epidermal LC with increasing melanoma thickness;
however, even in earlier stages of melanoma evolution (melanoma in
situ and superficially invasive melanoma), alterations in LC density and
distribution, although minor, were significant.
Alterations in the density and distribution of LC during the evolution of
primary melanoma are likely to be significant in the processes leading to
the development of melanoma-directed immunity, and such immunity
may have the capacity to slow local tumor progression and inhibit the
development of metastases [6]. To delineate better the alterations of LC
frequency, distribution, and phenotype that occur as melanoma evolves,
we have extended our studies using two reliable phenotypic markers for
LC – S-100 protein [7] and CD1 [8,9] – and examined a larger number of
lesions, including some that represented the earlier stages of development
of melanoma.
MATERIALS AND METHODS
Tissue samples were obtained from 46 patients with histologically
proved malignant melanoma. There were 23 frozen blocks of tissue
from primary melanomas removed in the Department of Dermatol-
ogy at the Justus-Liebig University in Giessen, Germany. This tissue
was snap-frozen at the time of removal and stored at 70 1C and was
air freighted to Los Angeles packed on solid carbon dioxide. It was
necessary to obtain frozen tissues in this way because, in Los
Angeles, most primary melanomas are removed by private derma-
tologists outside the university setting. In Giessen, many patients
with suspicious pigmented tumors were referred to the Department
of Dermatology and managed by Eberhard Paul, who was able to
identify lesions of interest and freeze portions of tumor not required
for diagnostic purposes. We additionally examined sections from 23
formalin-fixed, paraffin-embedded blocks of tissue from melanomas
of patients attending the Division of Surgical Oncology, University of
California Los Angeles (UCLA).
Reagents These were normal swine serum (Dako, Santa Barbara,
CA); normal horse serum (Vector Laboratories, Burlingame, CA);
biotinylated horse anti-mouse immunoglobulin (Ig) G (Vector);
swine anti-rabbit IgG (Vector); alkaline phosphatase (AKP) staining/
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developer kits (Vector); and peroxidase-anti-peroxidase conjugates
(Dako). Antibodies used were rabbit anti-bovine S-100 protein (Dr.
Zoreh Farzad, Department of Surgery, UCLA); anti-HLA-DR; anti-
leukocyte common antigen (LCA) (Dako); and anti-CD 1, -CD4, -
CD5, -CD8, -CD 14, -CD 16, and -CD22 (Becton-Dickinson,
Mountainview, CA).
Immunostaining Tissue slices (o10mm 4mm) for CD1 immuno-
peroxidase staining were removed from unfixed surgical specimens
within 1 h of surgery. As far as possible, slices included evaluable
amounts of clinically normal, lesion-adjacent and lesion-containing
skin. Slices were immediately embedded in OCT (Lab-Tek Division,
Miles Laboratories, Naperville, IL), snap-frozen in an isopentane/dry
ice bath, and stored at 70 1C until cryostat sectioning. These blocks
were vertically sectioned (5 mm, 20 1C) dermal edge first, placed on
acetone-cleaned microscope slides, fixed in dry acetone (4 1C) for
5min, and air-dried for 2 h. Sections from all cases were incubated
with antibody to CD1 (1–4mg/ml) subsequently with biotinylated
horse anti-mouse IgG and finally with peroxidase-conjugated biotin-
avidin complexes (Vector).
For and-S-100 protein (S-100) staining, archived paraffin blocks
were selected to provide evaluable areas of lesion and normal
adjacent skin. Normal melanocytes were distinguished from LC by
their basal location and relatively weak staining with anti-S-100
protein. Paraffin-embedded tissues were processed as described
previously [10]. They were incubated with a polyclonal rabbit anti-
bovine S-100 protein anti-serum (1:50–1:200 dilution), followed by
swine anti-rabbit Ig, and finally amino-ethyl carbazole.
Double-Labeling Technique Paraffin-embedded sections were depar-
affinized. Sections (paraffin or frozen) were then exposed to 3% H2O2
for 10min to quench endogenous peroxidases. After washing, normal
serum was applied for 20min. The two primary antibodies under study
(mouse anti-CD1, rabbit anti-S-100) were applied for 45min and the
sections then washed for 5min in Tris buffer. A secondary antibody
reagent, consisting of biotinylated IgG and swine anti-rabbit IgG, was
applied for 30min. During this incubation, the tertiary reagents were
prepared. After washing for 5min, peroxidase – anti-peroxidase
immune complexes and an AKP staining reagent (biotin-avidin
complex/AP kit) were applied for 30–60min. After a wash in Tris
buffer amino-ethyl carbazole was applied for 5–10min, after which the
sections were washed in tap water for 5min. The AKP developer (AKP
substrate kit) was applied for 20–30min in the dark, after which the
sections were finally washed in tap water for 5min before being
mounted in glycerol-gelatin.
Image Analysis All immunohistology slides were analyzed using an
IBM PC-assisted image analysis system (Southern Micro-comp
Instruments, Atlanta, GA). At 40 , every 300-mm width of skin
was further magnified 10 , detected by a Dage black-and-white
video camera, displayed on a Sony monitor, and evaluated for the
presence of cell bodies that stained positively for CD1 or S-100
protein. All LC that had a visible cell body and were located
between the stratum granulosum and the epidermal basement
membrane were counted and the density of cells/square millimeter
of epidermis assessed. Occasional melanocytic cells trasversing the
epidermis were identifiable by their non-dendritic morphology and
large size relative to the LC body. The image analyzer was
concomitantly used accurately to compute epidermal area for each
300-mm width of skin. Data are reported as epidermal LC density/
square millimeter of epidermis and as dermal DC count/square
millimeter of dermis. Stratum corneum and melanocytic nests do not
contain LC and were not included in measurements of epidermal
area. Adnexa-related epithelium, which generally has more LC than
surface epidermis, was also excluded. Dermal DC, T (CD5) and B
(CD22) lymphocytes, T-helper-inducer cells (CD4), T-suppressor-
cytotoxic cells (CD8), macrophages (CD14), and natural killer (NK)
cells (CD16) were counted per square millimeter of dermis using the
image-analysis system.
Data Analysis Comparisons between data from tumor-containing
and normal fields within an individual case (mean±s.d.) or between
groups of similarly designated lesions (mean±s.e.m.) were eval-
uated by the Wilcoxon rank sum test and paired t test, respectively.
RESULTS
Normal Skin Adjacent to Melanoma Examination of skin peripheral to the
invasive tumor edge and away from any radial growth phase (melanoma
in situ) that was present showed no abnormality of melanocyte frequency
or morphology. In 14 samples of normal epidermis adjacent to primary
melanomas, there were 224±24 S-100þ LC/mm2 (range 86–458) and
291±18 CD1þ LC/mm2(range 173–375) (Table I). The difference
between these values is statistically significant (Po0.01) (paired t test).
The majority of LC in normal epidermis (77%) thus express both S-100
and CD1, but a minority are S-100/CDlþ . In the dermis of normal skin
peripheral to the tumor, DC occur at low frequency (Table II) (13±2 S-
100þ DC/mm2 [range 1–44]; 17±2 CD1þ DC/mm2 [range 7–33]). As in
normal epidermis adjacent to the melanoma, the majority of DC in
normal dermis express both S-100 and CD1. Neither lymphocytes nor
macrophages were seen in normal epidermis. Lymphoid cells were sparse
in samples of normal dermis adjacent to tumor: LCAþ cells (70±13/mm2;
range 0–249); CD5þ T cells (14±3/mm2; range 0–54); CD4þ helper-
inducer cells (8±3/mm2; range 0–52); CD8þ suppressor-cytotoxic cells
Table I. Comparison of Frequency of Langerhans Cells in the Epidermis Over and Adjacent to Primary Melanoma
Using Two Markers, S-100 Protein and CD1
Epidermis Over Primary Melanoma Epidermis Adjacent to Primary Melanoma
Marker Preparationa nb x¯±s.e.m.c Range nb x¯±s.e.m.c Range
S-100 protein Formalin 14 112±18 4–206 14 224±24 86–458
CD1 Frozen 11 206±22 100–343 11 291±18 173–375
aFormalin-fixed, paraffin-embedded, or frozen-section material.
bTotal number of specimens examined. The number of cases presented reflects the availability of sufficient tissue to permit a valid comparison of normal and
tumor-associated tissues in frozen and/or paraffin-embedded material.
cMean values of LC/mm2 epidermis±s.e.m.
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(4±3/mm2; range 0–29); and CD22þ B cells (1±1/mm2; range 0–14).
Neither CD 14þ macrophages nor CD16þ NK cells were seen in normal
dermis (Table II).
Langerhans Cells in the Epidermis Overlying Melanoma In 15 of 19
melanomas (79%), there were fewer S-100þ LC in the epidermis
overlying tumor (112±18 LC/mm2; range 40–206) than in normal
tumor-adjacent epidermis (224±24 LC/mm2; range 86–458; Po0.0005)
(Table I and Table III). In contrast, only 11 of 24 melanomas (46%)
showed a significant reduction in the number of CD1þ LC in the
epidermis overlying tumor (206±22 LC/mm2) compared with normal
epidermis (291±18 LC/mm2; Po0.0005). A reduction in S-100þ LC was
seen in more tumors than was a diminution of CD1þ LC (79 and 46%,
respectively). The degree of reduction was also greater for S-100þ cells
than for CD1þ cells (60 and 30%, respectively; Po0.025). In the
epidermis overlying primary melanoma, the frequency of LC that express
both S-100 protein and CD 1 is reduced (54%), and the frequency of LC
that express CD1 but lack S-100 protein (46%) is increased relative to that
seen in normal epidermis.
The reduction in S-100þ /CDlþ LC was least in in situ and
superficially invasive melanoma (Clark levels I and II, 3 of 5, 36±5%;
range 25–37%) and significantly greater in deeper melanomas (Clark level
III–V, 9 of 11, 76±7%; range 56–97%). The reduction in frequency of
S-100þ LC was less in thin primary melanomas (o0.76mm, 5 of 7,
42±9%; range 37–87%) than in thicker tumors (40.76mm, 7 of 8,
63±9%; range 13–97%).
Significant reductions in LC frequency were seen in fewer specimens,
and the extent of LC reduction was less when the marker was CD1 [11 of
24 (46%), 30±5%; range 4–70%]. Reductions in CD1þ LC were most
prominent in in situ and superficially invasive melanoma [6 of 11 (55%)]
and occurred in a minority of deep melanomas [Clark level III–V, 3 of 9
(33%)]. The extent of reduction of CD1þ LC was similar in superficial and
deeper melanomas (31±5% and 31±9%, respectively). The reduction in
CD1þ LC was similar in thin primary melanomas [o0.76mm, 5 of 7
(71%), 26±5%; range 9–42%] and in thicker tumors [40.76mm, 6 of 12
(50%), 33±6%; range 18–60%].
Dendritic Cells in the Dermis Deep to Melanoma S-100þ DC were
present in the dermis deep to all melanomas examined (59±9/mm2;
range 4–127) (Table II). S-100þ DC were more frequent in the dermis
deep to melanoma in situ (104±23/mm2) than in the dermis deep to
invasive melanoma (36±15/mm2; range 4–55). S-100þ dermal DC were
more frequent in thinner melanomas (o0.76mm, 76±32), than in thicker
primary melanomas (40.76mm, 32±16; Po0.05). The ratio of LCAþ
leukocytes to S-100þ dermal DC varied from 5.5 to 15.5, being highest
when many LCAþ cells were present.
CD1þ DC were also present in the dermis deep to melanoma in all
cases (43±9/mm2; range 4–200) and represented a proportion of total
dermal leukocytes that varied from 1–30% (average 13%). In the dermis,
the frequency of S-100þ DC is similar to that of CD1þ cells, suggesting
that most if not all dermal DC coexpress S-100 protein and CD1.
Relationship Between the Frequencies of Epidermal and Dermal
Langerhans Cells We correlated the decrease in S-100þ LC in the
epidermis over tumor relative to normal epidermis (mean –60%) with the
increase in frequency of S-100þ DC in the dermis deep to tumor relative
to normal dermis (meanþ 347%) and the increase in the frequency of
dermal LCAþ cells (meanþ 627%). There was a weak but statistically
significant correlation between the decrease in epidermal LC and the
increase in dermal LC (r¼ 0.5783; Po0.05). Presumably the correlation is
relatively weak because many of the epidermal Langerhans cells (ELC)
that migrate into the dermis do not stay there but travel via the afferent
lymphatics to the lymph nodes. There was no correlation between
percentage decrease in ELC and percentage increase in LCAþ leukocytes
(r¼ 0.4339; P40.10).
Non-Dendritic Leukocytes in the Dermis Adjacent to Melanoma These
were examined in sections from 23 tumors (Table II). All showed an
increased frequency of leukocytes in the dermis deep to the tumor,
relative to adjacent normal dermis (see above). CD5þ T cells were
present at an average density of 519±82/mm2 but ranged from 19 to
1725/mm2. A similar density of leukocytes was found in the dermis deep
to 23 formalin-fixed, paraffin-embedded tumors when LCA was sought
Table II. Distribution of Leukocytes in the Dermis Deeper than and Peripheral to Primary Melanoma
Dermis Beneath Tumor Dennis Peripheral to Tumor
Cell Type (Marker)a nb x¯±s.e.m.c Range nb x¯±s.e.m.c Range
Total leukocytes (LCA)d 23 439±59 62–1190 22 70±13 0–249
T lymphocytes
CD5e 23 519±82 19–1725 12 14±3 0–54
CD4e 23 407±74 4–1700 12 8±3 0–52
CD8e 22 178±47 0–1004 12 4±3 0–29
NK cells(CD16)e 23 0 0 12 0 0
B cells (CD22)e 23 13±2 0–185 12 1±1 0–14
Macrophages (CD14)e 22 27±19 0–350 12 0 0
Dendritic cells
S-100d 22 59±9 4–127 21 13±2 1–44
CDl+
e
22 43±9 4–200 21 17±2 7–33
aFor more details and sources of reagents,see Materials and Methods.
bNumber of specimens examined.
cMean values of appropriately stained cells/mm2 dermis±s.e.m.
dFormalin-fixed, paraffin-embedded material.
eFrozen-section material.
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(439±59 leukocytes/mm2; range 62–1190). The majority of lymphocytes
present were of the CD4 subset (407±74/mm2; range 4–1700), with fewer
CD8 T cells (178±47/mm2; range 0–1004). The CD4: CD8 ratio averaged
4.1:1, with a range from 1.3 to 21.
Scattered CD14þ macrophages were seen in most sections (27±19/mm2;
range 0–350), as were occasional CD22þB cells (13±2/mm2; range 0–185).
CD16þ NK cells were not seen. As noted above, dermal DCþ positive for
both CD1 and S-100 were present in most cases and represented between 1
and 30% of total dermal leukocytes. Leukocyte density was maximal in the
dermis deep to thinner and more superficial tumors [e.g., LCAþ leukocytes
(melanoma in situ, 1087±104/mm2; invasive melanoma, 352±185/mm2)
(o0.76mm, 823±295; 40.76mm, 282±145].
DISCUSSION
These data confirm our previous observation [5] that there is a decline in
the frequency of LC in the epidermis overlying primary melanoma. This
was observed whether the LC marker used was S-100 protein or CD1. The
decline was considerably greater when S-100 was the marker than when
CD1 was used. The situation is, however, more complicated than
previously appreciated because in addition to the numerical reduction in
LC, we identified concurrent alterations in LC/DC phenotype.
Epidermal DC in animals and in humans are phenotypically
heterogeneous [11]. Although some of these variations may indicate a
different cellular lineage for subsets of DC, others relate to the stage of DC
maturity and activation status. We have observed that most LC in normal
human epidermis (77%) express S-100 and CD1 (S-100þ /CD1þ ), and in
double-labeling studies, S-100 and CD1 are coexpressed on the same DC
(A-MA Lana and D-R Wen, unpublished). In contrast, in the epidermis
overlying a primary melanoma, only 54% of LC are S-100þ /CD1þ , the
remaining cells being S-100/CD1þ . At the same time, there is an
increase in the frequency of DC in the dermis subjacent to the primary
melanoma. In normal dermis, the few DC present were mainly (77%)
S100þ / CD1þ , and coexpression of these markers has again been
confirmed by double-staining studies. This proportion of S-100þ /CD1þ
DC is identical to that seen in normal epidermis. The remaining DC were,
as is the case in normal epidermis, S-100/CD1þ . In the dermis deep to
primary melanoma, the proportion of DC that are S-100þ / CD1þ (73%) is
similar to that in normal epidermis and dermis. It is, however, striking that
the balance of DC in the dermis deep to primary melanoma (23%) are S-
100þ /CD1, a phenotype that was not encountered in normal epidermis
or dermis or in the epidermis over primary melanoma. This may indicate
that these cells are not of LC lineage.
There is strong evidence from studies in humans and experimental
animals that under conditions of antigenic stimulation, for example, the
induction of contact sensitivity [12], ELC develop alterations of their
phenotype and migrate through the epidermal basement membrane to the
dermis [13]. It is considered that these phenotypic alterations are initial
steps in a series of events associated with the conversion of LC from cells
that can efficiently acquire antigen, but have a limited ability to present
antigen to naive T lymphocytes, to cells that efficiently present antigen in
the nodal paracortex [14]. From these studies, it is implicit that LC that
reach the dermis subsequently pass via the afferent lymphatics to the
regional lymph nodes. From our data, LC traffic between normal
epidermis and dermis is balanced in terms of the phenotype of the
trafficking cells. The low density of DC in normal dermis points to the rate
of traffic being low, but absolute proof of this could only be obtained from
kinetic studies. Kinetic studies would also rule out the remote possibility
that the switch of the ELC from S-100/CD1þ to S-100/CDlþ is due to in
situ alteration of the phenotype of the ELC rather than emigration of S-
100þ /CD1þ LC from the epidermis to the dermis and beyond. The
situation is very different in the immediate vicinity of a primary
melanoma. There is a substantial reduction in S-100þ /CDlþ LC in the
epidermis and an increase of such cells in the peritumoral dermis,
suggesting that an outflow of ‘‘mature’’ LC occurs in association with
stimuli provided by tumor evolution and with the development of the
infiltrate of lymphocytes and macrophages that is characteristic of primary
melanoma early in its evolution [15]. The absolute increase in S-100þ /
CD1þ dermal DC is less than the absolute decrease in such cells in the
overlying epidermis, but it is most probable that this results from the
migration of many epidermally derived LC to the regional nodes via the
afferent lymphatics. It is not at present clear whether S-100þ /CDlþ
dermal DC are all LC en route to the nodes or whether some are arrested
in this site and actually present antigen to lymphocytes in situ. Studies to
investigate the latter possibility will require the analysis of dermal DC-
associated T lymphocytes for expression of activation markers, such as
HLA-DR [16] and the receptor for interleukin-2 [17], and a search for high
endothelial venules and markers of endothelial activation [18].
The minority population of cells in the dermis deep to melanoma that
are S-100þ /CD1 is of interest. We have not identified such cells in
normal epidermis or dermis or in the epidermis over primary melanoma
and consider that they may be of a different lineage from LC. They may be
dendritic macrophages that have phagocytosed S-100 protein released
from melanoma cells. In future studies, we plan to apply immunomarkers
for macrophage lineage to these cells to clarify this situation.
We examined the density and phenotype of non-dendritic leukocytes
present in tumor-associated and adjacent normal dermis and attempted to
relate these findings to the frequency of dermal DC. As in our own
previous studies [15] and those of others interested in the constitution of
melanoma-associated leukocytic infiltrates [19,20], we found that most
Table III. Langerhans Cells in the Epidermis Over Cutaneous Primary Melanoma Relative to the Adjacent Normal
Epidermis
S-100+ LC Declinea CD1+ LC Decline
Melanoma R/Tb (%) x¯±s.e.m.c Range R/Tb (%) x¯±s.e.m.c Range
All 15/19 (79) 60±23 13–96 11/24 (46) 30±5 4–70
Clark levels I+II 3/5 (60) 36±5 25–37 6/11 (55) 31±9 4–70
Clark levels III–V 9/11 (82) 76±7 56–97 3/9 (33) 31±5 20–43
o0.76mm 5/7 (71) 42±9 37–87 5/7 (71) 26±5 9–42
40.76mm 7/8 (88) 63±9 13–97 6/12 (50) 33±6 18–60
a100 ðmeanof residual number of ELC in epidermis over tumorÞðmean of ELC in adjacent normal skinÞ 100
bNumber of specimens showing reduction of ELC/total specimens.
cMean±standard error of mean of percentage reduction in number of ELC.
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cells present were CD5þ T lymphocytes and that the majority of these
were CD4 cells, the mean ratio of CD4: CD8 being 4.1:1. The density of T
lymphocytes present varied widely, with maximum numbers being seen
in thinner and superficial tumors. Macrophages and B lymphocytes were
relatively infrequent, and NK cells were not identified.
The ratio of non-dendritic to dendritic leukocytes in the dermis deep to
primary melanoma ranged from 3:1 to 100:1. We were unable to relate
these variations in ratio to tumor thickness or depth of invasion. We
consider that it will be important in future studies to seek relationships to
the presence or absence of lymphocytes infiltrating the tumor tissues, an
appearance that probably indicates the presence of an active immune
response that is aggressively attacking the melanoma cells. Wallace Clark,
the worthy honoree of this festschrift, has demonstrated that there are
differences in the biologic significance of melanoma-associated lymphoid
populations that relate to whether lymphoid cells actually penetrate
between tumor cells or remain aggregated in the peritumoral stroma [21],
and we have previously related the recurrence tendency of primary
melanoma to the presence and density of tumor-associated lymphoid
infiltrates [22]. Variations in the DC: non-DC leukocyte ratio may reflect
the current antigen-presenting activity of the dermal DC, and in future
studies we will address this by relating the density, morphology, and
immunophenotype of dermal DC to the presence of activation markers on
lymphocytes associated with the dermal DC and to the presence or
absence of high endothelial venules and endothelial activation markers,
as evidence that there is a local active immune response.
In summary, we consider that these initial studies clearly indicate the
need for further phenotypic, kinetic (and functional) studies of the DC of
the tissues adjacent to and influenced by primary cutaneous melanoma.
Such studies will need simultaneously to examine a wide range of
phenotypic markers as indices of cell lineage and immunologic
activation. It is likely that the yield from this approach will be substantial,
providing new and critical information on the processes by which tumor-
associated antigens are acquired in the skin and transported to the
regional nodes and there presented to T lymphocytes. We believe that
tumor-derived molecules can impede this process [6] and consider that
disruption of antigen presentation may be of central importance in the
generation of tumor-induced immune dysfunction of the regional nodes
and the suppression of tumor-associated lymphoid infiltrates. Extension of
the studies described in this review may be expected to provide important
insights into this potentially critical area of tumor biology.
These studies were supported by grants CA 29938 and 43658 awarded by the National Cancer
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